Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | SMMT |
---|---|---|
09:32 ET | 32376 | 8.08 |
09:34 ET | 90859 | 8.25 |
09:36 ET | 20721 | 8.17 |
09:38 ET | 2900 | 8.02 |
09:39 ET | 200 | 8.04 |
09:41 ET | 206 | 8.07 |
09:43 ET | 21300 | 8.107 |
09:45 ET | 2971 | 8.085 |
09:48 ET | 34295 | 8.12 |
09:50 ET | 1622 | 8.11 |
09:52 ET | 8811 | 8.19 |
09:54 ET | 13360 | 8.2199 |
09:56 ET | 15853 | 8.18 |
09:57 ET | 5959 | 8.15 |
09:59 ET | 1950 | 8.13 |
10:01 ET | 2961 | 8.17 |
10:03 ET | 5738 | 8.13 |
10:06 ET | 7500 | 8.14 |
10:08 ET | 7088 | 8.23 |
10:10 ET | 23549 | 8.22 |
10:12 ET | 4150 | 8.22 |
10:14 ET | 21268 | 8.31 |
10:15 ET | 21456 | 8.28 |
10:17 ET | 10415 | 8.28 |
10:19 ET | 6494 | 8.315 |
10:21 ET | 65327 | 8.43 |
10:24 ET | 16711 | 8.4001 |
10:26 ET | 9432 | 8.43 |
10:28 ET | 27513 | 8.44 |
10:30 ET | 13460 | 8.38 |
10:32 ET | 10001 | 8.34 |
10:33 ET | 13494 | 8.3 |
10:35 ET | 11460 | 8.336 |
10:37 ET | 2024 | 8.35 |
10:39 ET | 3341 | 8.38 |
10:42 ET | 5222 | 8.3607 |
10:44 ET | 1859 | 8.385 |
10:46 ET | 4447 | 8.345 |
10:48 ET | 11790 | 8.35 |
10:50 ET | 6943 | 8.345 |
10:51 ET | 14234 | 8.3633 |
10:53 ET | 2682 | 8.3832 |
10:55 ET | 4372 | 8.37 |
10:57 ET | 4367 | 8.365 |
11:00 ET | 300 | 8.365 |
11:02 ET | 2136 | 8.35 |
11:04 ET | 6179 | 8.38 |
11:06 ET | 5847 | 8.37 |
11:08 ET | 12915 | 8.33 |
11:09 ET | 2217 | 8.32 |
11:11 ET | 14768 | 8.28 |
11:13 ET | 846 | 8.29 |
11:15 ET | 1756 | 8.28 |
11:18 ET | 5965 | 8.2899 |
11:20 ET | 34185 | 8.2106 |
11:22 ET | 18032 | 8.225 |
11:24 ET | 1550 | 8.215 |
11:26 ET | 3700 | 8.1801 |
11:27 ET | 2619 | 8.16 |
11:29 ET | 100 | 8.18 |
11:31 ET | 3000 | 8.13 |
11:33 ET | 7299 | 8.13 |
11:36 ET | 9484 | 8.11 |
11:38 ET | 10989 | 8.0708 |
11:40 ET | 6798 | 8.09 |
11:42 ET | 1351 | 8.12 |
11:44 ET | 8760 | 8.09 |
11:45 ET | 1868 | 8.11 |
11:47 ET | 4950 | 8.165 |
11:49 ET | 2628 | 8.16 |
11:51 ET | 3868 | 8.13 |
11:54 ET | 3054 | 8.1381 |
11:56 ET | 10205 | 8.145 |
11:58 ET | 4007 | 8.16 |
12:00 ET | 2824 | 8.14 |
12:02 ET | 9141 | 8.115 |
12:03 ET | 2881 | 8.125 |
12:05 ET | 11647 | 8.08 |
12:07 ET | 7206 | 8.11 |
12:09 ET | 838 | 8.15 |
12:12 ET | 1000 | 8.15 |
12:14 ET | 900 | 8.135 |
12:16 ET | 1219 | 8.12 |
12:18 ET | 5376 | 8.13 |
12:20 ET | 300 | 8.145 |
12:21 ET | 600 | 8.13 |
12:23 ET | 1574 | 8.15 |
12:25 ET | 4636 | 8.15 |
12:27 ET | 4823 | 8.19 |
12:30 ET | 3703 | 8.15 |
12:32 ET | 3165 | 8.17 |
12:34 ET | 1500 | 8.18 |
12:36 ET | 2354 | 8.21 |
12:38 ET | 2346 | 8.24 |
12:39 ET | 5274 | 8.2 |
12:41 ET | 2099 | 8.22 |
12:43 ET | 1940 | 8.24 |
12:45 ET | 2376 | 8.24 |
12:48 ET | 2535 | 8.24 |
12:50 ET | 7999 | 8.28 |
12:52 ET | 10087 | 8.29 |
12:54 ET | 2100 | 8.27 |
12:56 ET | 5969 | 8.23 |
12:57 ET | 500 | 8.23 |
12:59 ET | 2332 | 8.23 |
01:01 ET | 3657 | 8.2 |
01:03 ET | 3451 | 8.175 |
01:06 ET | 400 | 8.175 |
01:08 ET | 2080 | 8.185 |
01:10 ET | 673 | 8.17 |
01:12 ET | 2942 | 8.2 |
01:15 ET | 12769 | 8.18 |
01:17 ET | 600 | 8.18 |
01:19 ET | 1889 | 8.18 |
01:21 ET | 300 | 8.18 |
01:24 ET | 300 | 8.17 |
01:26 ET | 5050 | 8.2 |
01:28 ET | 800 | 8.19 |
01:30 ET | 297 | 8.19 |
01:32 ET | 3393 | 8.17 |
01:33 ET | 2281 | 8.17 |
01:35 ET | 100 | 8.14 |
01:37 ET | 1789 | 8.13 |
01:39 ET | 100 | 8.145 |
01:42 ET | 3184 | 8.12 |
01:44 ET | 2429 | 8.14 |
01:46 ET | 300 | 8.14 |
01:48 ET | 400 | 8.15 |
01:50 ET | 2038 | 8.1501 |
01:51 ET | 1800 | 8.18 |
01:53 ET | 1747 | 8.15 |
01:55 ET | 1433 | 8.16 |
01:57 ET | 313 | 8.14 |
02:00 ET | 200 | 8.15 |
02:02 ET | 400 | 8.15 |
02:04 ET | 3569 | 8.15 |
02:06 ET | 201 | 8.14 |
02:08 ET | 756 | 8.16 |
02:09 ET | 601 | 8.17 |
02:11 ET | 1590 | 8.16 |
02:13 ET | 500 | 8.15 |
02:15 ET | 4582 | 8.18 |
02:18 ET | 1199 | 8.19 |
02:20 ET | 500 | 8.22 |
02:22 ET | 1120 | 8.205 |
02:24 ET | 562 | 8.215 |
02:26 ET | 1600 | 8.215 |
02:27 ET | 300 | 8.21 |
02:29 ET | 5255 | 8.205 |
02:31 ET | 2741 | 8.18 |
02:33 ET | 1900 | 8.18 |
02:36 ET | 1308 | 8.17 |
02:38 ET | 4725 | 8.1927 |
02:40 ET | 4830 | 8.17 |
02:42 ET | 100 | 8.15 |
02:44 ET | 3283 | 8.185 |
02:45 ET | 800 | 8.175 |
02:47 ET | 2800 | 8.16 |
02:49 ET | 1700 | 8.14 |
02:51 ET | 1600 | 8.14 |
02:54 ET | 7272 | 8.15 |
02:56 ET | 2725 | 8.14 |
02:58 ET | 14850 | 8.17 |
03:00 ET | 109 | 8.16 |
03:02 ET | 4834 | 8.1425 |
03:03 ET | 200 | 8.14 |
03:05 ET | 2857 | 8.15 |
03:07 ET | 3454 | 8.15 |
03:09 ET | 1400 | 8.14 |
03:12 ET | 8538 | 8.13 |
03:14 ET | 300 | 8.14 |
03:16 ET | 4289 | 8.14 |
03:18 ET | 21342 | 8.12 |
03:20 ET | 1200 | 8.1 |
03:21 ET | 15001 | 8.13 |
03:23 ET | 3308 | 8.14 |
03:25 ET | 1100 | 8.14 |
03:27 ET | 3366 | 8.15 |
03:30 ET | 14383 | 8.125 |
03:32 ET | 12709 | 8.1 |
03:34 ET | 8836 | 8.1075 |
03:36 ET | 37238 | 8.08 |
03:38 ET | 5686 | 8.08 |
03:39 ET | 35724 | 8.04 |
03:41 ET | 15922 | 8.05 |
03:43 ET | 12762 | 8.0299 |
03:45 ET | 18611 | 8.03 |
03:48 ET | 64020 | 8.025 |
03:50 ET | 14936 | 8.03 |
03:52 ET | 20960 | 8.07 |
03:54 ET | 16662 | 8.03 |
03:56 ET | 72426 | 8.01 |
03:57 ET | 71717 | 7.995 |
03:59 ET | 98594 | 8.01 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Summit Therapeutics Inc | 5.6B | -48.4x | --- |
Madrigal Pharmaceuticals Inc | 6.0B | -12.1x | --- |
Viking Therapeutics Inc | 5.3B | -51.4x | --- |
Nuvalent Inc | 5.2B | -33.4x | --- |
Cytokinetics Inc | 6.1B | -9.8x | --- |
Immunitybio Inc | 5.0B | -6.9x | --- |
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.6B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 702.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.97 |
EPS | $-0.17 |
Book Value | $0.11 |
P/E Ratio | -48.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.